Emad Ahmed, MD
Nephrology · Athens, GANPI 1144394883
Payments from drug & device makers
Across 256 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$610
- AstraZeneca$476
- Daiichi Sankyo Inc.$426
- OPKO Pharmaceuticals, LLC$399
- Akebia Therapeutics Inc$352
- Vifor Pharma, Inc.$349
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,24492%
- Education$3858%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $610 |
| AstraZeneca(2 entities) | 27 | $476 |
| Daiichi Sankyo Inc. | 21 | $426 |
| OPKO Pharmaceuticals, LLC | 20 | $399 |
| Akebia Therapeutics Inc | 21 | $352 |
| Vifor Pharma, Inc. | 21 | $349 |
| Novartis | 11 | $282 |
| Travere Therapeutics, Inc. | 32 | $258 |
| Mallinckrodt Hospital Products Inc. | 8 | $239 |
| Aurinia Pharma U.S., Inc. | 10 | $206 |
| Otsuka America Pharmaceutical, Inc. | 7 | $157 |
| Boehringer Ingelheim | 6 | $128 |
| Bayer | 6 | $109 |
| Fresenius USA Marketing, Inc. | 6 | $107 |
| GSK | 5 | $97 |
| Lilly USA, LLC | 4 | $77 |
| Novo Nordisk | 3 | $53 |
| AMAG Pharmaceuticals, Inc. | 3 | $50 |
| Calliditas Therapeutics US Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Masimo Corporation | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
How this compares
$4,629 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 236 | $168,338 |
| VelphoroSucroferric Oxyhydroxide | 33 | $73,712 |
| RayaldeeCalcifediol | 49 | $59,699 |
| AuryxiaFerric Citrate | 27 | $44,756 |
| JardianceEmpagliflozin | 51 | $39,069 |
| JanuviaSitagliptin Phosphate | 38 | $28,806 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $28,108 |
| Sevelamer Carbonate | 88 | $25,024 |
| EliquisApixaban | 33 | $17,739 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $17,623 |
| ProsolParenteral Amino Acid 20% No.1 | 91 | $15,042 |
| DapagliflozinDapagliflozin Propanediol | 18 | $9,031 |
| EntrestoSacubitril/Valsartan | 18 | $7,609 |
| Clonidine | 42 | $5,872 |
| Calcium Acetate | 44 | $3,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $476 | $196,446269 claims |
| Fresenius USA Marketing, Inc.Velphoro | $107 | $73,71233 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $399 | $59,69949 claims |
| Akebia Therapeutics IncAuryxia | $352 | $44,75627 claims |
| Boehringer IngelheimJardiance | $128 | $39,06951 claims |
| NovartisEntresto | $282 | $7,60918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.
Other nephrology in Athens
- Srilakshmi RebalaAthens$18K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.